Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
OCSAW
Upturn stock ratingUpturn stock rating

Oculis Holding AG Warrants (OCSAW)

Upturn stock ratingUpturn stock rating
$7.45
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: OCSAW (3-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Number of Analysts

rating

0 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

Analysis of Past Performance

Type Stock
Historic Profit 75.18%
Avg. Invested days 23
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 4.0
Stock Returns Performance Upturn Returns Performance 4.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta -
52 Weeks Range 1.85 - 11.50
Updated Date 02/26/2025
52 Weeks Range 1.85 - 11.50
Updated Date 02/26/2025
Dividends yield (FY) -
Basic EPS (TTM) -

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -
Return on Equity (TTM) -

Valuation

Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating -
Shares Outstanding -
Shares Floating -
Percent Insiders -
Percent Institutions -

ai summary icon Upturn AI SWOT

Oculis Holding AG Warrants

stock logo

Company Overview

overview logo History and Background

Oculis Holding AG is a biopharmaceutical company dedicated to developing innovative ophthalmic treatments. While specific warrant history requires real-time data lookup, warrants are typically issued in conjunction with a SPAC merger or financing rounds to provide investors with the right to purchase shares at a specified price.

business area logo Core Business Areas

  • Pharmaceutical Development: Focuses on developing and commercializing innovative ophthalmic treatments for various eye diseases.

leadership logo Leadership and Structure

Leadership details and organizational structure unavailable without real-time data lookup. Typically, a warrant issuing company has a board of directors and executive management team.

Top Products and Market Share

overview logo Key Offerings

  • OCU400: A novel therapy addressing genetic retinal diseases; Market share data is not yet established. Potential competitors include companies developing gene therapies for retinal diseases.
  • OCU200: Investigational treatment for dry eye disease; Market share data is not yet established. Competitors include Allergan (ABBV) (Restasis), Novartis (NOVN) (Xiidra) and other companies with dry eye products.

Market Dynamics

industry overview logo Industry Overview

The ophthalmic pharmaceutical industry is experiencing growth driven by aging populations, increasing prevalence of eye diseases, and advancements in treatment options, particularly in gene and cell therapies.

Positioning

Oculis Holding AG aims to be a leader in ophthalmic innovation through novel treatments for unmet needs.

Total Addressable Market (TAM)

The global ophthalmology market is estimated to be worth billions of dollars. Oculis is positioning itself to capture a portion of this TAM through its novel therapies.

Upturn SWOT Analysis

Strengths

  • Innovative pipeline of ophthalmic treatments
  • Focus on unmet medical needs
  • Potential for breakthrough therapies

Weaknesses

  • Limited commercialized products
  • Reliance on clinical trial success
  • Requires significant capital for R&D

Opportunities

  • Expanding ophthalmic market
  • Partnerships with larger pharmaceutical companies
  • Regulatory approvals for novel therapies

Threats

  • Competition from established pharmaceutical companies
  • Clinical trial failures
  • Regulatory hurdles
  • Generic drugs eating up market share from novel therapies

Competitors and Market Share

competitor logo Key Competitors

  • ABBV
  • NOVN
  • ALNY
  • LLY

Competitive Landscape

Oculis Holding AG aims to compete with established players by developing innovative ophthalmic therapies. Its success depends on clinical trial outcomes and regulatory approvals.

Growth Trajectory and Initiatives

Historical Growth: Historical growth data unavailable without access to financial reports.

Future Projections: Future projections depend on clinical trial results, regulatory approvals, and market adoption.

Recent Initiatives: Recent initiatives likely include clinical trial advancements and potential partnerships.

Summary

Oculis Holding AG is a biopharmaceutical company focused on ophthalmic diseases. They are in the early stages of commercialization, having innovative therapies in development. Their long-term success hinges on clinical trial results and regulatory approvals. The company faces competition from larger, established pharmaceutical companies and needs to manage its cash flow carefully while advancing its pipeline. Warrant valuation depends on the stock reaching the strike price.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Market Research Reports

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Financial data and market share estimates are based on available information and may be subject to change. Warrant value is speculative.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Oculis Holding AG Warrants

Exchange NASDAQ
Headquaters -
IPO Launch date 2023-03-03
CEO -
Sector Healthcare
Industry Biotechnology
Full time employees 32
Website
Full time employees 32
Website

Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. Its product candidates in development includes OCS-01, a topical retinal candidate for diabetic macular edema; OCS-02, a topical biologic candidate for dry eye disease; and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.